Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization

Decera Clinical Education Oncology Podcast · Mar 20, 2026 · 25m

In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.

Presenters:

Rodney Hunter, PharmD, BCOP

Director of Clinical Services

Memorial Hermann Texas Medical Center

Clinical Pharmacy Specialist

University of Texas Health Memorial Hermann Cancer Center

Professor

Texas Southern University College of Pharmacy and Health…